Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors

NCT02250885 is registered in ClinicalTrials.gov with Gabrail Cancer Center Research as lead sponsor.

NCT NCT02250885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02250885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Lead sponsor
Gabrail Cancer Center Research
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2014
Completion date
August 31, 2016
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, neuroendocrine